Kornimate/medical-research-clean huggingface dataset:
a patient reminder and self-referral via online patient portals and text messaging to improve adherence to breast cancer screening

Conditions: Breast Carcinoma

Summary: this clinical trial evaluates the patient reminders and self-referrals via online patient portals and text messaging (prevent) intervention for improving adherence to breast cancer screening. though no doctor referral is required for mammography, adherence to screening mammograms remains low. barriers to screening mammography can include things like forgetfulness, low motivation, high cost, or lack of knowledge. patient reminders and self-scheduling assistance may overcome some of these barriers by increasing patients' awareness, motivating them to schedule their mammogram, and improving access by removing the need for a healthcare provider to order the exam. the prevent intervention uses online and text-message based patient-reminders and self-referral assistance to increase adherence to breast cancer screening.

primary objectives; i. compare the screening mammogram (sm) completion rates between prevent and enhanced usual care (euc) arms at 6 months. ii. describe patient's experience with the prevent intervention using mixed methods stratified by completion of sm. outline: participants are randomized to 1 of 2 arms. arm i: participants receive usual care as well as a portal message reminder to schedule a sm and a callback link if they need assistance. participants who have not or do not schedule their sm at the time of the first reminder receive a reminder text-message one week later with a link to receive assistance with scheduling. arm ii: participants receive usual care as well as portal and text messages one week apart with educational materials about healthy eating. after completion of study, patients are followed up at 6 months.

Eligibility criteria:
inclusion criteria: * women aged 50-74 years * active online patient portal account * mobile phone number listed in the electronic medical record (emr) * at least one primary care visit in our healthcare system between 2015 and 2021 * no screening mammography performed in our healthcare system in the last 2 years exclusion criteria: * because of limited research team and patient portal language at this time, non-english speaking patient will be excluded * personal history of breast cancer or prior mastectomy * participants who already have an upcoming sm scheduled within or outside of emory healthcare * patients who had a screening mammography at an outside facility within the prior 2 years * patients with severe comorbidities at the time of the study (in palliative care or hospitalized at the time of the study) * participants who are cognitively impaired or have with history of alzheimer's disease or dementia
managing outpatient hysteroscopy-associated pain

Conditions: Pain; Hysteroscopic Surgery

Summary: hysteroscopy is a reference diagnostic and therapeutic procedure in intrauterine pathologies, increasingly performed without general anesthesia. pain is the most common reason for discontinuation of outpatient hysteroscopy (oh). there is no consensus on pain alleviation during oh. the aim was to compare the effectiveness of pain relief options during oh.

a prospective randomized trial (consent no.1072.6120.228.2021) includes women subjected to oh due to focal uterine lesion, abnormal uterine bleeding, or infertility. women are randomly assigned to 3 arms - a: nsaid (ketoprofen 100 mg intravenously), b: a+infiltration anesthesia (20 ml 1% lidocaine), c: a+paracervical block (20 ml 1% lidocaine). karl storz 5.0 mm bettocchi® operative sheath with 2.9 mm 30 degree telescope and 5 fr working channel was used. intensity of pain in numeric rating scale (nrs), intensity of cervical bleeding, frequency of vaso-vagal reaction, and frequency of abandoning/ limiting the procedure were compared.

Eligibility criteria:
inclusion criteria: * age over 18 * indications for hysteroscopy: focal uterine lesion, abnormal uterine bleeding, or infertility exclusion criteria: * allergies to medications * refusal to consent to the procedure or participation in the study
effectiveness of assessment and educational intervention on motor control of the pelvic floor muscle in women

Conditions: Menopause; Perimenopausal Disorder

Summary: the goal of the present study is to evaluate the short and long term effectiveness of a tailored assessment and educational intervention on motor control of the pelvic floor muscle in menopausal and non-menopausal women.

menopausal transition has been related to stress urinary incontinence. the transition from the reproductive to the non-reproductive period is induced by a decrease in sex hormone production in the ovaries. climacteric-stage oestrogen deficiency produces genital and urinary tract atrophy, which may be related to symptoms such as urinary frequency, urinary urgency, nocturia incontinence, and recurrent urinary tract infection. urinary incontinence seems to appear due to a combination of factors such as pelvic floor weakness and tearing, denervation and fascial tears as well as both loss of motor units and altered activation patterns. however, physiotherapy can treat weakness and altered motor control in order to compensate for other factors. in fact, physiotherapy is considered the treatment of first choice. besides evidence defending physiotherapy as first line conservative therapy in incontinence due to influence of strength and motor control in this pathology and its prevalence in perimenopause women, little is known about its effects in this population. hence, the aim of this study is to evaluate the short and long term effectiveness of a tailored assessment and educational intervention on motor control of the pelvic floor muscle in menopausal and peri-menopausal women.

Eligibility criteria:
inclusion criteria: * all participants in this study will sign an informed consent form prior their inclusion, and that whose participation will be voluntary exclusion criteria: * participants will be excluded if they have any cognitive disability, physical disability or psychiatric limitations that could limit the participation on the study test

Keywords: pelvic floor muscles pelvic floor muscle training motor control educational intervention menopause
removal of dermal exposure to phthalate ester by hand washing

Conditions: Environmental Exposure; Exposure to Pollution

Summary: the aim of the study is to evaluate the effectiveness in removing chemical exposure on hand, the investigators compare removal efficiency of di-(2-ethylhexyl)phthalate (dehp) on hands by hand washing with soap and water vs. water only. in two three-day n-of-1 trials, residual dehp was measured in a single female adult who washed exposed hands with soap-and-water or water-only. subsequently, a crossover study was performed by randomly assigning another 28 subjects equally to wash with soap-and-water or with water-only, and then each one received the other treatment 24 hrs later.

three studies, consisting of two n-of-1 trials and one crossover study, were used to compare the effect of handwashing with soap and water (intervention) and handwashing with water only (placebo) on phthalate removal from hands. the soap was plain soap, consisting of vegetable oil and sodium hydroxide. first, the investigators recruited one healthy female aged 25 yrs to participate in two n-of-1 trials. in each trial, her hands would be exposed to dehp and then be treated with either soap intervention or placebo for three times over the course of three days. the first trial started on 15 may 2013. on day one, after the subject prewashed her hands, she allowed her hands to be exposed to a designated amount of dehp. she then washed them with water only and rinsed them sequentially in three separate polyethylene (pe) bags, each containing 200 ml water to collect dehp residue. one hour later, the same protocol was followed, except the exposed hands were treated with soap and water instead of water only (figure 1a). the water rinsing in three separate bags remained the same. the pairs of studies were repeated on two subsequent days (16 and 17 may). in the second n-of-1 trial, which was also performed over three days (22-24 may), the protocol using the same subject remained the same for all three days, except that the subject underwent intervention first then placebo. the water rinsing remained the same. a randomized 2 × 2 crossover study was subsequently conducted between june and september 2013. the investigators assigned one group of 7 females and 7 males to perform handwashing with soap and water (intervention) and another group of 7 females and 7 males to perform handwashing with water only (placebo). briefly, on the first day, the two groups washed their dehp exposed hands using either soap and water or water only and then rinsed them in a pe bag with 200 ml water to collect dehp. after 24 hrs, the experiment was crossed-over with the same two groups receiving the opposite treatments.

Eligibility criteria:
inclusion criteria: * healthy adult over age of 18 years * bmi\>18 exclusion criteria: * diagnosis of any type of cancers, dermatitis, asthma * cut, abrasion, and trauma on hands * bmi \<18

Keywords: diethylhexyl phthalate hand hygiene soaps n-of-1 design cross-over studies
randomized phase ii trial of letrozole with or without dasatinib as first and second-line treatment for hormone receptor-positive, her2-negative post-menopausal breast cancer that is unresectable, locally recurrent or metastatic

Conditions: Metastatic Breast Cancer

Summary: the purpose of this study is to find out what effect the combination of letrozole (brand name: femara) and dasatinib (brand name: sprycel) has on metastatic breast cancer compared to letrozole alone


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * has histologic or cytologic diagnosis of breast cancer; evidence of unresectable locally recurrent or metastatic disease * has measurable or evaluable-only disease * is female, ≥18 yrs of age, post menopausal or surgically sterile * her2 negative, hr+, er+ and/or pgr+ breast cancer * 0-1 prior chemotherapy regimen for metastatic disease. * prior adjuvant or neoadjuvant chemotherapy completed at least 1 month prior * prior tamoxifen therapy is allowed * no ai therapy for \>1 year without recurrence exclusion criteria: * pregnant or breast feeding * prior hormonal therapy for metastatic or locally recurrent disease * \>1 chemotherapy regimen for metastatic disease * pleural or pericardial effusion * serious cardiac condition
evaluation of the cost of a nosocomial infection with clostridium difficile

Conditions: Cross Infection; Clostridium Difficile Infection

Summary: clostridium difficile is the first cause of nosocomial infectious diarrhea, due to its mode of transmission and its resistance in the environment. nosocomiality is defined by the apparition of an infection 48 hours after the patient's hospitalization. clostridium difficile contamination occurs oro-fecally and is transmitted directly through the hand or from the contaminated environment (during care or not). by implementing prevention and optimal treatment, nosocomial infections are preventable. a clostridium difficile infection causes an additional cost of patient care for the hospital. this additional cost is principally due to the increase of the length of the stay. it varies according to patient risk factors,and also according to the reason of the hospitalization and can vary from 300 euros (\~317$) to more than 25.000 euros (26.460$). by determining the increase in the length of the stay and the additional cost due to a clostridium difficile infection in the ghicl (groupement des hôpitaux de l'institut catholique de lille), prevention will be valued and measures against those infections should be easier to set up. the main objective of this study is to evaluate the additional cost of an infection by clostridium difficile.


Eligibility criteria:
inclusion criteria: * patients that have stayed in an hospital of the ghicl between january 2013 and september 2015. exclusion criteria: * none
tongxinluo capsule for coronary microvascular disease

Conditions: Coronary Microvascular Disease

Summary: to investigate the efficacy and safety of tongxinluo in patients with microvascular angina pectoris. long-term follow-up of 1 to 5 years will be performed to evaluate the effect of tongxinluo on long-term adverse cardiovascular events in patients with coronary microvascular disease.


Eligibility criteria:
inclusion criteria: 1. repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks; 2. coronary normal or stenosis \< 20%; 3. ischemic depression in st segment during resting or exercise; 4. blood flow reserve (cfr) of the anterior descending coronary artery \< 2.0; 5. subjects or their guardians agreed to participate in this study. exclusion criteria: 1. previous myocardial infarction or pci or cabg treatment; 2. a history of heart failure or lvef \< 50%; 3. severe arrhythmia; 4. myocarditis, pericardium disease, valvular disease, or cardiomyopathy; 5. a history of stroke within half a year; 6. diabetes difficult to control; 7. refractory hypertension or hypertension accompanied by left ventricular wall thickness \> 12 mm; 8. familial hypercholesterolemia; 9. takayasu arteritis, kawasaki disease or coronary artery malformation; 10. pregnant or nursing, or having the intention to give birth within one year; 11. hepatic or renal dysfunction; 12. other diseases which may cause serious risks to patients; 13. requiring warfarin anticoagulant therapy; taking potassium channel opener, ccb, acei drugs or traditional chinese medicines; 14. allergic to contrast agents or blood products; 15. patients who participated in clinical research of other drugs within 3 months before being selected.
short term outcomes of laparoscopic intraperitoneal onlay mesh with facial repair(ipom-plus) for ventral hernia.

Conditions: Hernia

Summary: entral hernias are a major cause of functional impairment, abdominal pain, and bowel obstruction. the overall incidence of primary ventral hernia is estimated to be between 4 and 5 % in the literature, and ventral incisional hernia rates vary from 35 to 60 % within 5 years after laparotomy . after laparoscopy, this rate is estimated to decline from 0.5 to 15 % even after two decades, lvhr or open repair (ovhr) is still a matter of debate because of concerns about seroma formation, recurrence rate, and the intraperitoneal mesh position. . the laparoscopic technique for repairing ventral and incisional hernias is now well established. however, several issues related to lvhr, such as the high recurrence rate of hernias with large fascial defects and in extremely obese patients, are yet to be resolved. additional problems include seroma formation. to solve these problems, laparoscopic fascial defect closure with ipom reinforcement (ipom-plus) has been introduced in the past decade, and a few studies have reported satisfactory outcomes. although detailed techniques for fascial defect closure and handling of the mesh have been published, standardized techniques are yet to be established.


Eligibility criteria:
inclusion criteria: * patients over 18 years undergoing surgery for primary or incisional ventral hernia * defect whose major axis not exceeding 12cm. exclusion criteria: * patients undergoing revision * emergency surgery. * parastomal hernias were not included. * patients not candidate for laparoscopy including cardiac and copd patients

Keywords: ventral hernia - lvhr-transfacial repair
adjunctive local application of lidocaine during scleral buckling under general anesthesia

Conditions: Retinal Detachment

Summary: the purpose of this study is to evaluate the effect of topical lidocaine in scleral buckling surgery.


Eligibility criteria:
inclusion criteria: * retinal detachment * retinal tear less than 3 hour clock exclusion criteria: * vitreous hemorrhage * proliferative vitreoretinopathy
vestibular function after chemoradiotherapy for nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: nasopharyngeal carcinoma (npc) is usually treated with chemoradiotherapy. while the effects of this treatment on cochlear function is well characterized, its effect on vestibular function is not well studied. in this study the investigators will study the vestibular function of 50 patients undergoing chemoradiotherapy for npc both before and after treatment in order to better define its effects. all patients will undergo a validated questionnaire (dizziness handicap index), posturography, audiometry and vestibular-evoked myogenic potentials.


Eligibility criteria:
inclusion criteria: * age 18 years or older. * biopsy-proven npc. * about to undergo chemoradiotherapy with intensity-modulated radiotherapy (imrt). exclusion criteria: * pregnancy. * prior vestibular dysfunction.

Keywords: vestibular function chemoradiotherapy
efficacy and safety with albumin-bound paclitaxel (abraxane) in the tac as neoadjuvant chemotherapy in breast cancer

Conditions: Breast Cancer

Summary: select 60 cases of women with breast cancer at clinical stage of t1-4n0-2m0. then treat them with 4 cycles of tac (abraxane 260mg/m2,epi 60 mg/m2 ,ctx 500 mg/m2, 21day/cycle) as neoadjuvant chemotherapy. finally the investigators assess the efficacy and safety of albumin-bound paclitaxel.

the investigators select 60 cases of women with breast cancer at clinical stage of t1-4n0-2m0. then treat them with 4 cycles of tac (abraxane 260mg/m2,epi 60 mg/m2 ,ctx 500 mg/m2, 21day/cycle) as neoadjuvant chemotherapy. finally the investigators assess the efficacy and safety of albumin-bound paclitaxel.

Eligibility criteria:
inclusion criteria: 1. karnofsky ≥ 70 2. provision of informed consent 3. pathological confirmation of breast cancer 4. tumor stage (tnm):t2-4bn0-3m0 5. measurable disease as per recist criteria 6. not previously treated with radiotherapy, chemotherapy or biological therapy. 7. laboratory criteria: * plt ≥ 100\*109/l * wbc ≥ 4000/mm3 * hgb ≥ 10g/dl * got,gpt,alp ≤ 2\*uln * tbil,dbil,ccr ≤ 1.5\*uln exclusion criteria: 1. pregnant woman 2. history of organ transplantation 3. with mental disease 4. with severe infection or active gastrointestinal ulcers 5. with severe liver disease (such as cirrhosis), kidney disease, respiratory disease or diabetes 6. disease-free period of other malignant tumor is less than 5 years (except cured basal cell skin cancer and cervical carcinoma in situ) 7. with heart disease 8. experimental drug allergy
morphecos - evaluation of the influence of fatigue and sleep on the performance of 2nd cycle medical students (osce)

Conditions: Fatigue Intensity; Sleep; Sleep Deprivation; Circadian Rhythm

Summary: objective and structured clinical examinations (osces) has been incorporated recently in the certification process as a final national undergraduate ranking examination. this exam is a challenge for medical students. the aim of this study is to better characterise the population of students taking the osces on the subject of sleep and fatigue and to assess whether these factors have an impact on their performance in the osces.


Eligibility criteria:
inclusion criteria: * subjects of legal age, enrolled in the 2nd cycle médical program at the lyon est faculty of medicine (claude bernard lyon 1 university), taking part in the annual session (february or march 2025) of the faculty's osces and having agreed to participate by completing and signing the dedicated written consent form. exclusion criteria: * abstenteism or premature end to the osce session.
clinical and pathologic studies in non-hodgkin's lymphoma patients receiving antibody treatment

Conditions: Lymphoma, Non-Hodgkin; Lymphomas: Non-Hodgkin; Lymphomas: Non-Hodgkin Cutaneous Lymphoma; Lymphomas: Non-Hodgkin Diffuse Large B-Cell; Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell; Lymphomas: Non-Hodgkin Mantle Cell; Lymphomas: Non-Hodgkin Marginal Zone; Lymphomas: Non-Hodgkin Peripheral T-Cell; Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia

Summary: to characterize the molecular and cell biology of the tumor cells in lymphoma. the mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.


Eligibility criteria:
inclusion criteria:non-hodgkin's lymphoma patients receiving antibody treatment
magnetic resonance fingerprinting in the imaging of endometrial cancer

Conditions: Endometrial Cancer

Summary: in this context, the aim of this study is to investigate the role of mrf in endometrial cancer. several applications are possible. firstly, t1-, t2- and dwi-mappings can be associated to molecular risk group classification, in order to stratify patients' risk without recurring to surgery. mrf parameters can be also correlated to prognosis, both in terms of disease-free survival (dfs) and overall survival (os).


Eligibility criteria:
inclusion criteria: * patients with biopsy-proven endometrial cancer; * women aged \> 18 years old; * signed informed consent. exclusion criteria: * previous history of neoplasm; * concurrent malignancies at other sites.
motivation project: testing intervention components for the smoker who is unwilling to quit

Conditions: Smoking; Motivation; Smoking Cessation

Summary: the ultimate goal of this research is to develop a chronic care treatment package for smokers that will address the challenges and opportunities of each phase of the cessation process - motivation, preparation, cessation, maintenance, and relapse recovery. that is, to develop treatments for smokers not yet ready to quit, those who are preparing to quit, those actively engaged in the quitting process and those who have tried to quit but relapsed. to achieve this goal, this research comprises three distinct research studies, each of which represent a phase in a comprehensive chronic care treatment model for clinical intervention with smokers in the primary care setting: the motivation study, the cessation study, and the long-term quitting study. the goal of each study is to test and identify effective intervention components for distinct phases of the smoking cessation process. these components will then be combined for future research on the effectiveness of this chronic care treatment package. this study is a 2x2x2x2 factorial design. participants will be randomized to one of two levels on four different factors: 1) nicotine mini-lozenge vs. no mini-lozenge, 2) behavioral reduction counseling (intervention: br) vs. no behavioral reduction counseling, 3) 5rs motivation counseling (intervention 5 r's) vs. no 5rs motivation counseling, and 4) behavioral activation counseling (intervention ba) vs. no behavioral activation counseling. these components have strong theoretical and empirical support, but their relative, additive, and interactive effects are unknown.


Eligibility criteria:
inclusion criteria: * age \>=18 years; smoking \>4 cigarettes/day for the previous 6 months; able to read, write, and speak english; have reliable phone access and agree to respond to interactive voice response (ivr) phone prompts; and if currently using nrt, agreeing to use only study medication for the duration of the study. we will not exclude participants based on their prior use of cessation medication or if they use multiple tobacco products in order to enhance real-world generalization (these will be statistically controlled in analyses); not currently attempting to quit smoking; not intending to quit smoking (defined as no plans to quit in the next month); and planning to remain in the intervention catchment area for at least 12 months. exclusion criteria: * currently taking bupropion or varenicline; medical contraindications to using nrt including hospitalized (for at least one night) for a stroke, heart attack, congestive heart failure or diabetes in the last 30 days; diagnosis of or treatment for schizophrenia, a psychotic disorder or bipolar disorder in the last 10 years; and, if the participant is a woman of childbearing potential, being pregnant or intending to becoming pregnant or unwillingness to use an approved method of birth control during treatment.

Keywords: nicotine